BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//iceps-mdivd - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:iceps-mdivd
X-ORIGINAL-URL:https://iceps-mdivd.org
X-WR-CALDESC:Events for iceps-mdivd
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20261008T140000
DTEND;TZID=Europe/Brussels:20261008T153000
DTSTAMP:20261008T123550Z
CREATED:20260827T152615Z
LAST-MODIFIED:20261008T123550Z
UID:10000012-1791468000-1791473400@iceps-mdivd.org
SUMMARY:Insights into the EU Joint Clinical Assessment (JCA) for Medical Devices and In Vitro Diagnostics
DESCRIPTION:Get ready for the new EU JCA framework and understand what it means for your evidence strategy. \n8 October 2026 | 2:00 PM CET | Online \nAbout the Webinar\nThe EU Joint Clinical Assessment (JCA) is introducing a new approach to the clinical assessment of certain medical devices and in vitro diagnostics at European level. \nBut what does this mean in practice for manufacturers? \nThis webinar will provide a clear overview of the JCA framework and its practical implications\, from the Joint Scientific Consultation (JSC) process to evidence scoping using the PICO framework. \nThe session will also explore how manufacturers can prepare early\, anticipate evidence expectations and build an evidence strategy that supports both European-level assessment and national market access decisions. \nWhat Will We Cover?\nDuring this 90-minute webinar\, we will explore: \n\nThe JCA process and key timelines\nJoint Scientific Consultation (JSC)\nEvidence scoping and the PICO framework\nKey challenges manufacturers should anticipate\nPractical considerations for early evidence planning\n\nThe session will conclude with a live Q&A\, giving participants the opportunity to discuss their questions directly with the experts. \nWho Should Attend?\nThis webinar is particularly relevant for professionals working in: \nRegulatory Affairs • Clinical Development • Market Access • HEOR • Medical Devices & IVDs • Health Technology Assessment \nSpeakers\nRachel Hoad\nDirector of Market Access\, Lightning Health \nRachel holds a PhD in Cell Physiology and Pharmacology from the University of Leicester and a First-Class Undergraduate Masters degree in Molecular and Cellular Biology from the University of Bath. \nRachel has over a decade of experience in market access consultancy\, working across pharmaceuticals\, medical devices\, drug-device combinations and digital health. Her therapy area expertise is varied and includes dermatology\, rare diseases\, oncology\, HIV and NASH. \nIn a previous roles she has been responsible for providing strategic oversight to research projects to ensure overall objectives were met. She has extensive project experience that ranges from mapping and understanding the European market for medical devices and diagnostics\, including TPP testing\, product positioning\, HTA and reimbursement landscapes\, procurement routes and price potential. \nAdam Ben Taied\nSenior Consultant\, Lightning Health \nAdam Ben Taieb: Adam holds a First-Class Honours Degree in Biomedical Science from the University of Surrey\, and an MSc in Science Communication from the University of Manchester. Adam has 7+ years experience working in the market access strategy and value communication field\, working with pharmaceutical and medical device companies throughout their products lifecycle\, to optimise their commercial potential\, value and market access strategy. \nAdam has experience in leading and delivering an extensive range projects\, from early disease landscaping\, pricing opportunity assessments and launch strategy development\, through to evidence generation\, value tools\, HTA submissions\, and stakeholder insights. His experience spans across numerous global markets as well as disease areas\, including rare diseases\, cardiology\, neurology\, respiratory\, diabetes etc. \nPractical Information\n\nDate: 8 October 2026\nTime: 2:00 PM CET\nFormat: Online via Zoom\nRegistration Fee: Free for ICEPS members and 20€ for non-members (VAT excl.)\nZoom Access: The Zoom link and connection details will be sent by email.\nRecording: The session will be recorded\, and access to it will be only for ICEPS members\n\nImportant Information\nPlease note that this event is a webinar only. \nParticipants will have the opportunity to ask questions and exchange directly with the expert speaker. \nThis session is not a training course\, and participation does not provide a certificate of attendance\, training completion\, or certification. \nYour Zoom access link is personal and may not be shared. Any participant not registered through ICEPS may be removed from the webinar without notice. \nThe session is recorded and only available for ICEPS members. \n 
URL:https://iceps-mdivd.org/event/insights-into-the-eu-joint-clinical-assessment-jca-for-medical-devices-and-in-vitro-diagnostics/
LOCATION:Zoom  Webinar
ATTACH;FMTTYPE=image/png:https://iceps-mdivd.org/wp-content/uploads/2026/08/261008-Insight-into-the-EU-Joint-Clinical-Assessment-.png
END:VEVENT
END:VCALENDAR